CHANGES OF mRNA CASPASE-3 AFTER FIRST CYCLE OF CHEMOTHERAPY AS BIOMARKER ASSOCIATE TO CHEMOTHERAPY NEGATIVE RESPONSE IN LOCALLY ADVANCED BREAST CANCER

• Main Authors: I K. Widiana, I. B. T. Wibawa-Manuaba, K. Siki-Kawiyana, I W. P. Sutirta-Yasa
• Format: Article
• Language: English
• Published: DiscoverSys 2015-08-01
• Series: Bali Medical Journal
• Subjects: mrna, caspase-3, neoadjuvant, chemotherapy, locally advanced breast cancer
• Online Access: https://balimedicaljournal.org/index.php/bmj/article/view/118
• ISSN: 2089-1180; 2302-2914

<span>Background: Problems caused by behaviour of biology molecular in locally advanced breast cancer still unpredictable. This study aims to identify the mRNA caspase-3 as a predictive biomarker associated to chemotherapy sensitivity following neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer. Methods: Open biopsy before and core biopsy after first cycle neoadjuvant chemotherapy of 62 locally advanced breast cancer patients was analysed for mRNA caspase-3 by Reverse Transcription - Polymerase Chain Reaction (RT-PCR) and this was correlate with response to NAC using American Joint Committee on Cancer (AJCC) creteria. Results: The total mean of mRNA caspase-3 expression before chemotherapy was 12.51±3.03 and after chemotherapy was 11.64±3.13. Negative response to chemotherapy was 44 (70.96%) and positive response was 18 (29.03%). The result of data with Phi and Cramer’s V analysed showed that decrease of mRNA caspase-3 after chemotherapy first cycle as a risk factor to chemotherapy negative response in patients with locally advanced breast cancer was significantly (p = 0.007). Conclusion: Decrease of mRNA caspase-3 after chemotherapy first cycle correlated with chemotherapy negative response in patients with lacally advanced breast cancer.</span>